Clinical data | |
---|---|
Trade names | Veraflox, Pradalex |
License data | |
Routes of administration | By mouth, intramuscular, subcutaneous |
ATCvet code | |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.169.611 |
Chemical and physical data | |
Formula | C21H21FN4O3 |
Molar mass | 396.422 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Pradofloxacin, sold under the brand name Veraflox among others, is a third-generation enhanced spectrum veterinary antibiotic of the fluoroquinolone class. [5] It was developed by Elanco Animal Health GmbH and received approval from the European Commission in April 2011, for prescription-only use in veterinary medicine for the treatment of bacterial infections in dogs and cats. [6] [7]
In the European Union, pradofloxacin is indicated for the treatment of: [8]
In the European Union, pradofloxacin is indicated for the treatment of: [8]
In the United States, pradofloxacin is indicated for certain respiratory diseases in cattle and swine. [5] It is approved for certain ages and classes of cattle for the treatment of bovine respiratory disease (BRD) associated with Mannheimia haemolytica , Pasteurella multocida , Histophilus somni , and Mycoplasma bovis . [5] It may only be prescribed for cattle intended for slaughter and cattle intended for breeding that are less than one year of age; it is not for use in cattle intended for breeding one year of age and older, beef calves less than two months of age, dairy calves, and veal calves. [5] It is approved for use in swine for the treatment of swine respiratory disease (SRD) associated with Bordetella bronchiseptica , Glaesserella (Haemophilus) parasuis , Pasteurella multocida , Streptococcus suis , and Mycoplasma hyopneumoniae . [5] It may only be prescribed for weaned swine intended for slaughter; it is not for use in swine intended for breeding or nursing piglets. [5]
The primary mode of action of fluoroquinolones involves interaction with enzymes essential for major DNA functions such as replication, transcription and recombination. The primary targets for pradofloxacin are the bacterial DNA gyrase and topoisomerase IV enzymes. Reversible association between pradofloxacin and DNA gyrase or DNA topoisomerase IV in the target bacteria results in inhibition of these enzymes and rapid death of the bacterial cell. The rapidity and extent of bacterial killing are directly proportional to the drug concentration. [8]
As a result, pradofloxacin is active against a wide range of Gram-positive and Gram-negative bacteria including anaerobic bacteria. [8]
Pradofloxacin was first discovered by chemists at Bayer in 1994 and patented in 1998. The name pradofloxacin was issued in December 2000 by the World Health Organization. Following submission for marketing authorisation to the European Medicines Agency (EMA) in 2004, the application was refused in 2006, [10] prompting further studies.
Having reviewed the additional studies, the EMA Committee for Medicinal Products for Veterinary Use (CVMP) recommended granting marketing authorisation of pradofloxacin by consensus in February 2011. [11] Marketing authorisation of pradofloxacin was granted by the European Commission in April 2011. [6]
Amoxicillin/clavulanic acid, also known as co-amoxiclav or amox-clav, sold under the brand name Augmentin, among others, is an antibiotic medication used for the treatment of a number of bacterial infections. It is a combination consisting of amoxicillin, a β-lactam antibiotic, and potassium clavulanate, a β-lactamase inhibitor. It is specifically used for otitis media, streptococcal pharyngitis, pneumonia, cellulitis, urinary tract infections, and animal bites. It is taken by mouth or by injection into a vein.
Ofloxacin is a quinolone antibiotic useful for the treatment of a number of bacterial infections. When taken by mouth or injection into a vein, these include pneumonia, cellulitis, urinary tract infections, prostatitis, plague, and certain types of infectious diarrhea. Other uses, along with other medications, include treating multidrug resistant tuberculosis. An eye drop may be used for a superficial bacterial infection of the eye and an ear drop may be used for otitis media when a hole in the ear drum is present.
Norfloxacin, sold under the brand name Noroxin among others, is an antibiotic that belongs to the class of fluoroquinolone antibiotics. It is used to treat urinary tract infections, gynecological infections, inflammation of the prostate gland, gonorrhea and bladder infection. Eye drops were approved for use in children older than one year of age.
Marbofloxacin is a carboxylic acid derivative third generation fluoroquinolone antibiotic. It is used in veterinary medicine under the brand names Marbocyl, Forcyl, Marbo vet and Zeniquin. A formulation of marbofloxacin combined with clotrimazole and dexamethasone is available under the name Aurizon.
Pefloxacin is a quinolone antibiotic used to treat bacterial infections. Pefloxacin has not been approved for use in the United States.
Florfenicol is a fluorinated synthetic analog of thiamphenicol, mainly used as a antibiotic in veterinary medicine.
Pasteurella multocida is a Gram-negative, nonmotile, penicillin-sensitive coccobacillus of the family Pasteurellaceae. Strains of the species are currently classified into five serogroups based on capsular composition and 16 somatic serovars (1–16). P. multocida is the cause of a range of diseases in mammals and birds, including fowl cholera in poultry, atrophic rhinitis in pigs, and bovine hemorrhagic septicemia in cattle and buffalo. It can also cause a zoonotic infection in humans, which typically is a result of bites or scratches from domestic pets. Many mammals and birds harbor it as part of their normal respiratory microbiota.
Cefquinome is a fourth-generation cephalosporin with pharmacological and antibacterial properties valuable in the treatment of coliform mastitis and other infections. It is only used in veterinary applications.
Prulifloxacin is an older synthetic antibiotic of the fluoroquinolone class undergoing clinical trials prior to a possible NDA submission to the U.S. Food and Drug Administration (FDA). It is a prodrug which is metabolized in the body to the active compound ulifloxacin. It was developed over two decades ago by Nippon Shinyaku Co. and was patented in Japan in 1987 and in the United States in 1989.
Tulathromycin, sold under the brand name Draxxin among others, is a macrolide antibiotic used to treat bovine respiratory disease in cattle and swine respiratory disease in pigs.
Difloxacin (INN), marketed under the trade name Dicural, is a second-generation, synthetic fluoroquinolone antibiotic used in veterinary medicine. It has broad-spectrum, concentration dependent, bactericidal activity; however, its efficacy is not as good as enrofloxacin or pradofloxacin.
Tylosin is a macrolide antibiotic and bacteriostatic feed additive used in veterinary medicine. It has a broad spectrum of activity against Gram-positive organisms and a limited range of Gram-negative organisms. It is found naturally as a fermentation product of Streptomyces fradiae.
Quinolone antibiotics constitute a large group of broad-spectrum bacteriocidals that share a bicyclic core structure related to the substance 4-quinolone. They are used in human and veterinary medicine to treat bacterial infections, as well as in animal husbandry, specifically poultry production.
Staphylococcus delphini is a Gram-positive, coagulase-positive member of the bacterial genus Staphylococcus consisting of single, paired, and clustered cocci. Strains of this species were originally isolated from aquarium-raised dolphins suffering from skin lesions.
Staphylococcus schleiferi is a Gram-positive, cocci-shaped bacterium of the family Staphylococcaceae. It is facultatively anaerobic, coagulase-variable, and can be readily cultured on blood agar where the bacterium tends to form opaque, non-pigmented colonies and beta (β) hemolysis. There exists two subspecies under the species S. schleiferi: Staphylococcus schleiferi subsp. schleiferi and Staphylococcus schleiferi subsp. coagulans.
Staphylococcus pseudintermedius is a gram-positive spherically shaped bacterium of the genus Staphylococcus found worldwide. It is primarily a pathogen for domestic animals, but has been known to affect humans as well. S. pseudintermedius is an opportunistic pathogen that secretes immune-modulating virulence factors, has many adhesion factors, and the potential to create biofilms, all of which help to determine the pathogenicity of the bacterium. Diagnoses of S. pseudintermedius have traditionally been made using cytology, plating, and biochemical tests. More recently, molecular technologies like MALDI-TOF, DNA hybridization and PCR have become preferred over biochemical tests for their more rapid and accurate identifications. This includes the identification and diagnosis of antibiotic resistant strains.
Bovine respiratory disease (BRD) is the most common and costly infectious disease affecting beef cattle in the world. It is a complex, bacterial or viral infection that causes pneumonia in calves which can be fatal. The infection is usually a sum of three codependent factors: stress, an underlying viral infection, and a new bacterial infection. The diagnosis of the disease is complex since there are multiple possible causes.
Zoliflodacin is an experimental antibiotic that is being studied for the treatment of infection with Neisseria gonorrhoeae (gonorrhea). It has a novel mechanism of action which involves inhibition of bacterial type II topoisomerases. Zoliflodacin is being developed by Innoviva Specialty Therapeutics, and the drug has demonstrated clinical efficacy equivalent to ceftriaxone in Phase III clinical trials.
Bovine respiratory syncytial virus (BRSV) is pneumovirus closely related to human respiratory syncytial virus (RSV) that is a common cause of respiratory disease in cattle, particularly calves. It is a negative-sense, single-stranded RNA virus that replicates in the cytoplasm of the cell. Similarly to other single-stranded RNA viruses, the genome of BRSV has a high mutation rate, which results in great antigenetic variation. Thus, BRSV can be split into four different subgroups based on antigen expression.
Tildipirosin, sold under the brand name Zuprevo is an antibiotic used in pigs and cattle.